Abstract B09: Targeting scavenger receptors for immunotherapy of cancer
Cancer immunology research(2020)
摘要
Background: Tumor-associated macrophages (TAM) play an important role in tumor-promoting inflammation and have been associated with poor prognosis in many human cancers. Recently, we showed that class A scavenger receptor MARCO is a specific marker for the immune-suppressive tumor-promoting TAM subtype in different tumor models. Targeting MARCO by monoclonal antibodies (Ab) could reprogram the protumorigenic TAM towards a proinflammatory phenotype with antitumor activity, leading to decreased tumor growth and metastases formation in three different mouse tumor models. Aim(s): The current immunotherapies are estimated to treat less than 50% of all cancers; therefore, it is of high importance to develop new targets and combinatorial therapies. In this study, we aim to define the role of scavenger receptor MARCO on TAM in more detail and the mechanisms of how targeting MARCO by monoclonal Ab modulates macrophage phenotype and tumor microenvironment. Moreover, we are investigating how it can be used as a possible anticancer therapeutic approach used as single or combinatorial treatment. Results: Our recent data demonstrate that using anti-MARCO Ab in combination with other immune checkpoint inhibitors, such as anti-CTLA-4 Ab, further decreases the tumor volume by 40-50% in the B16 melanoma model. For example, different checkpoint Ab combined with anti-MARCO Ab shows a reduction from average tumor volume 500mm3 in single treatments to 250mm3 (p=0.0101) in the combinatorial treatment. Currently, we are investigating what happens in the tumor microenvironment on a cellular level after using the different combinatorial treatments. Moreover, we see increased ATP release of MARCO+ macrophages in vitro after engagement of MARCO as well as enhanced glycolysis in anti-MARCO Ab treated macrophages compared to the control group. Conclusion: Checkpoint inhibitors targeting T cells are already used in the clinics and the anti-MARCO Ab targeting TAM is a promising candidate to use in combination with checkpoint inhibitors to even further increase the survival rate of patients. The understanding of MARCO signaling and how this leads to a shift towards proinflammatory macrophages would not just benefit the field of basic macrophage biology but will also be an important step in translating the anti-MARCO Ab therapy from mice to humans as a new approach for cancer immunotherapy. Citation Format: Vanessa F. Boura, Sofia Tyystjarvi, Ganna Oliynyk, Marie Arsenian-Henriksson, Mikael C.I. Karlsson, Silke Sohn. Targeting scavenger receptors for immunotherapy of cancer [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr B09.
更多查看译文
关键词
scavenger receptors,immunotherapy,abstract b09,cancer
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要